In the tumor, expression of Ch25h by venules or myeloid cells may help with initiating anti-tumor responses, as early B cell entry may promote tertiary lymphoid structure formation.52 Given the sufficiency of IFN-α/β and IFN-γ to induce Ch25h, we suggest that oxysterol EBI2 ligands may be more readily produced within tumors and at sites of inflammation than CCL21 and thus may have an early role in lymphocyte recruitment to these sites. The gene discussed is CCL21; the disease is neoplasm.